Share This Page
Drug Sales Trends for veregen
✉ Email this page to a colleague
Annual Sales Revenues and Units Sold for veregen
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| VEREGEN | ⤷ Subscribe | ⤷ Subscribe | 2021 |
| VEREGEN | ⤷ Subscribe | ⤷ Subscribe | 2020 |
| VEREGEN | ⤷ Subscribe | ⤷ Subscribe | 2019 |
| VEREGEN | ⤷ Subscribe | ⤷ Subscribe | 2018 |
| VEREGEN | ⤷ Subscribe | ⤷ Subscribe | 2017 |
| VEREGEN | ⤷ Subscribe | ⤷ Subscribe | 2016 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
Veregen Market Analysis and Financial Projection
Market Analysis and Sales Projections for Veregen
Introduction to Veregen
Veregen, a topical ointment derived from a defined extract of green tea leaves, is specifically designed for the local treatment of external genital and perianal warts (Condylomata acuminata)[1][4].
Market Context: Genital Warts Treatment
The global genital warts (condyloma acuminatum) market is anticipated to experience significant growth. As of 2023, the market is valued at approximately US$ 1.87 billion and is projected to reach US$ 3 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 4.84%[3][5].
Historical Sales and Revenue
Historically, Veregen has been a part of Medigene AG's product portfolio. In the first nine months of 2017, Veregen generated revenue of 1.8 million EUR from royalties, product sales, and milestone payments. Notably, over 50% of the annual Veregen revenue was derived from the US market[2].
US Market Rights
In December 2017, Medigene sold the US rights for Veregen to Fougera Pharmaceuticals, Inc., a dermatology business entity of Sandoz US, which is part of the Novartis group. This transaction included the transfer of intellectual property, licenses, know-how, and the trademark. Medigene retained the rights for Veregen outside the US and remained the exclusive supplier of the active pharmaceutical ingredient (API) to Fougera[2].
European Market
Veregen received positive assessments for market authorization from national regulatory authorities in Germany, Austria, and Spain in 2009. This approval paved the way for commercialization in these countries and other European nations via the Mutual Recognition Procedure. Medigene partnered with distribution companies such as Juste S.A.Q.F. for Spain and Portugal to expand its reach[4].
Recent Transactions and Impact
In 2019, Medigene sold its remaining rights and inventories of Veregen to Aresus Pharma GmbH. This transaction marked the completion of Medigene's transformation into a pure immunotherapy company. Medigene is set to receive up to approximately EUR 7.75 million from Aresus, with EUR 300,000 paid upfront and the balance to be received as annual revenue-based earn-out payments over the next ten years[1].
Financial Projections and Impact
The sale of US rights in 2017 positively impacted Medigene's financial guidance for that year. The company raised its revenue expectations to EUR 10.5-11.5 million and reduced its EBITDA loss forecast to EUR 14-15 million. However, the recent sale to Aresus will result in a non-cash effective loss between EUR 4 and 5 million, which will be compensated by interest income over the payment period[1][2].
Market Growth Drivers
Several factors are driving the growth of the genital warts market, including:
- Emerging Therapies: The anticipated launch of novel medications by key players such as Tamir Biotechnology, Verrica Pharmaceuticals, and Novan Inc. is expected to shift market dynamics[3][5].
- Vaccination Programs: Successful vaccination campaigns have increased public awareness and uptake of vaccines, leading to a lower incidence of genital warts[3][5].
- Healthcare Infrastructure: Improvements in healthcare infrastructure, particularly in emerging economies like China, India, and South Korea, are contributing to market growth[3].
Distribution Channels
Hospital pharmacies are expected to capture the largest share among distribution channels by 2033, driven by growing consumer awareness and increased investments in healthcare infrastructure across developing and underdeveloped economies[3].
Regional Growth
The Asia Pacific region is projected to observe the fastest growth throughout the forecast period, driven by swift economic development, improvements in healthcare infrastructure, and increased consumer awareness[3].
Key Takeaways
- Veregen is a significant player in the genital warts treatment market, derived from green tea extracts.
- The global genital warts market is expected to grow to US$ 3 billion by 2033 with a CAGR of 4.84%.
- Medigene AG has sold its US and remaining global rights for Veregen, completing its transformation into an immunotherapy company.
- Emerging therapies and vaccination programs are key drivers of market growth.
- Hospital pharmacies will dominate distribution channels, with the Asia Pacific region showing the fastest growth.
FAQs
What is Veregen used for?
Veregen is a topical ointment used for the local treatment of external genital and perianal warts (Condylomata acuminata)[1][4].
Who acquired the US rights for Veregen in 2017?
The US rights for Veregen were acquired by Fougera Pharmaceuticals, Inc., a part of the Novartis group[2].
What was the financial impact of selling the US rights for Veregen in 2017?
The sale raised Medigene's revenue expectations to EUR 10.5-11.5 million and reduced the EBITDA loss forecast to EUR 14-15 million for 2017[2].
Who acquired the remaining rights and inventories of Veregen from Medigene in 2019?
Aresus Pharma GmbH acquired the remaining rights and inventories of Veregen from Medigene in 2019[1].
What is the projected growth rate of the global genital warts market from 2023 to 2033?
The global genital warts market is projected to grow at a CAGR of 4.84% from 2023 to 2033[3][5].
Which region is expected to show the fastest growth in the genital warts market?
The Asia Pacific region is expected to observe the fastest growth throughout the forecast period[3].
Sources
- Medigene sells remaining rights and inventories of Veregen to Aresus Pharma - Medigene
- Medigene Sells U.S.-Rights for Veregen and Raises Financial Guidance - BioSpace
- Genital Warts (Condyloma Acuminatum) Market - Future Market Insights
- MediGene AG Receives Positive Assessment on Market Authorisation for Veregen - BioSpace
- Global Genital Warts (Condyloma Acuminatum) Market is expected to soar to US$ 3 Billion by 2033 - PharmiWeb
More… ↓
